CNTB Stock Forecast & Price Target

Connect Biopharma Hldgs is positioned favorably because rademikibart has shown differentiated, statistically significant efficacy in acute COPD, including an 81% reduction in treatment failure, an 85% reduction in new moderate/severe exacerbations, and a 100% reduction in hospital/ED returns, all while maintaining a favorable safety profile. The data also support a credible acute asthma pathway, with a 130-mL placebo-adjusted Day 7 FEV1 benefit in asthma and meaningful treatment-failure improvement despite low placebo event rates, suggesting the drug’s activity is not confined to one indication. With the market capitalization at roughly $70M and external validation from OBERON/TITANIA showing meaningful COPD event reductions without large FEV1 effects, the stock appears to be underappreciating the company’s clinical upside and potential registrational flexibility.

Connect Biopharma Hldgs is viewed negatively because its late-stage value remains highly dependent on rademikibart, yet the company still faces incomplete clarity on registrational endpoints, ongoing clinical uncertainty, and a likely need for a partner to fund COPD development and commercialization. Although Seabreeze STAT COPD showed an 81% reduction in treatment failure and no hospital or ED returns versus 8.6% for placebo, the asthma study did not reach statistical significance and several secondary endpoints were limited by low event counts. The investment case is further weakened by a potential cash overhang, runway guidance only through August 2027, up to $99M in outstanding Simcere milestones, and multiple stated risks including development, financing, regulatory, competitive, and delisting risk.